What is BCLI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BCLI?

P/E (TTM) is n/a and 52-week range is $0.46 to $1.69 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BCLI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BCLI?

The company profile lists net income (TTM) near $-22M, EPS (TTM) near $-2.02 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Brainstorm Cell Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 11M shares outstanding, ISIN US10501E3009 when available from company profile and filing metadata.

Brainstorm Cell Therapeutics Inc

$BCLI

Health Care · Biotechnology

IR Run Scenarios

$0.95

+3.92%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. The company is headquartered in New York City, New York and currently employs 20 full-time employees. The company went IPO on 2003-05-28. The firm is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The firm's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Employees

Website

brainstorm-cell.com/

IPO

2003-05-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)